Registered title, quoted from ClinicalTrials.gov
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05883852, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 70 years; sex: women only
Registered eligibility fields
Unilateral invasive carcinoma confirmed by histology (regardless of pathological type);
Inclusion criterion 3
Early breast cancer, pathologically confirmed as HER2 positive; HER2 positive definition: Immunohistochemical HER2 3+ or FISH/CISH test positive (with amplification) is defined as HER2 positive;
Inclusion criterion 5
Postoperative pathological stage pT1-4N1-3M0;
Inclusion criterion 6
If any tumor >T4a (accompanied by skin invasion, mass adhesion fixation, inflammatory breast cancer);
Exclusion criterion 4
The longest period from surgery to randomization was not more than 8 weeks, and no adjuvant therapy had been received after surgery;
Inclusion criterion 8
Women of childbearing age refuse contraception during treatment and within 8 weeks after completion of treatment;
Exclusion criterion 13
0-1 for ECOG;
Inclusion criterion 2
The major organs function normally, that is, meet the following criteria: (1) The standard of blood routine examination shall meet: HB ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5×109 /L; PLT ≥100×109 /L; (2) Biochemical examination should meet the following standards: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3 x ULN; Serum Cr ≤1.5×ULN;
Inclusion criterion 11
Patients with clinical or imaging suspicion of malignancy on the opposite breast but not confirmed, requiring biopsy;
Exclusion criterion 5
Malignant neoplasms (other than basal cell carcinoma of the skin and carcinoma in situ of the cervix), including contralateral breast cancer, within the previous 5 years;
Exclusion criterion 7
Pregnant and lactating women;
Exclusion criterion 14
Those who tested positive for pregnancy before taking the drug after joining the trial;
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05883852, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Women aged 18-70;
- 0-1 for ECOG;
- Unilateral invasive carcinoma confirmed by histology (regardless of pathological type);
- No gross or microscopic tumor remains after surgical resection;
- Early breast cancer, pathologically confirmed as HER2 positive; HER2 positive definition: Immunohistochemical HER2 3+ or FISH/CISH test positive (with amplification) is defined as HER2 positive;
- Postoperative pathological stage pT1-4N1-3M0;
- Did not receive neoadjuvant chemotherapy in the past;
- The longest period from surgery to randomization was not more than 8 weeks, and no adjuvant therapy had been received after surgery;
- No peripheral neuropathy;
- Good postoperative recovery, at least 1 week interval between operation;
- The major organs function normally, that is, meet the following criteria: (1) The standard of blood routine examination shall meet: HB ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5×109 /L; PLT ≥100×109 /L; (2) Biochemical examination should meet the following standards: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3 x ULN; Serum Cr ≤1.5×ULN;
- Contraception during treatment for women of reproductive age;
- Cardiac function: LVEF>50% for ultrasound examination;
- The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up。
Exclusion Criteria:
- Bilateral breast cancer or carcinoma in situ DCIS/LCIS;
- Have received chemotherapy for advanced disease;
- Transfer of any part;
- If any tumor >T4a (accompanied by skin invasion, mass adhesion fixation, inflammatory breast cancer);
- Patients with clinical or imaging suspicion of malignancy on the opposite breast but not confirmed, requiring biopsy;
- Have received neoadjuvant therapy, including chemotherapy, radiotherapy and endocrine therapy;
- Malignant neoplasms (other than basal cell carcinoma of the skin and carcinoma in situ of the cervix), including contralateral breast cancer, within the previous 5 years;
- The patient has been enrolled in other clinical trials;
- Patients with severe systemic disease and/or uncontrolled infection were unable to be enrolled in the study;
- LVEF<50% (cardiac ultrasound);
- Severe cardiovascular and cerebrovascular disease (e.g., unstable angina, chronic heart failure, uncontrolled hypertension >150/90mmgh, myocardial infarction or cerebrovascular accident) within 6 months prior to randomization;
- Known allergy to related drugs;
- Women of childbearing age refuse contraception during treatment and within 8 weeks after completion of treatment;
- Pregnant and lactating women;
- Those who tested positive for pregnancy before taking the drug after joining the trial;
- Mental illness, cognitive impairment, inability to understand the trial protocol and side effects, inability to complete the trial protocol and follow-up workers ;(systematic evaluation is required before trial enrollment);
- Persons without personal freedom and independent capacity for civil conduct。
Quoted from ClinicalTrials.gov, NCT05883852, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05883852, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.